Introduction
============

Esophagogastric junction outflow obstruction (EGJOO) is a clinically heterogenous manometric diagnosis.[@b1-jnm-25-075],[@b2-jnm-25-075] It is non-uniform diagnostic group and is considered a group of multiple clinical subsets. Additional tests such as barium esophagography, esophagogastroduodenoscopy, and endoscopic ultrasonography are needed because some patients have a structural cause of elevated integrated relaxation pressure (IRP).[@b1-jnm-25-075]--[@b5-jnm-25-075] However, most patients with EGJOO do not have a definite cause of IRP elevation.[@b4-jnm-25-075] In some patients, idiopathic EGJOO progresses to achalasia, and these patients show significant dysphagia and/or passage disturbance.[@b6-jnm-25-075]--[@b8-jnm-25-075] However, in a significant number of patients, elevated IRP is a coincidental finding without any clinical relevance.[@b2-jnm-25-075],[@b6-jnm-25-075] Recently, several studies have clearly shown that dysphagia and compartmentalized pressurization (CP) is closely related to clinically significant idiopathic EGJOO.[@b4-jnm-25-075],[@b9-jnm-25-075] In real practice, prediction of the clinical relevance of EGJOO is of great importance because of its diagnostic heterogeneity.

Multichannel intraluminal impedance (MII) of esophageal function was first described by Silny et al[@b10-jnm-25-075] in 1991. Impedance test allows detection and quantification of bolus movement by measuring differences in resistance to alternating current of the intraluminal contents.[@b11-jnm-25-075]--[@b13-jnm-25-075] Several studies that used combined videofluoroscopy and impedance validated the ability of impedance to evaluate bolus transit.[@b14-jnm-25-075],[@b15-jnm-25-075] The combined use of MII and high-resolution manometry (CMII-HRM) was reported to provide useful information about esophageal motility abnormality and the functional detail of bolus transit more precisely.[@b12-jnm-25-075],[@b16-jnm-25-075]--[@b19-jnm-25-075] In addition to clinicomanometric variables, bolus transit measured using MII, a parameter of the functional aspect of the esophageal contraction, may provide additional clinical information in patients diagnosed as having EGJOO on HRM.[@b16-jnm-25-075]

Our study aims to investigate whether evaluation of bolus transit by using MII is useful for discriminating clinically relevant EGJOO.

Materials and Methods
=====================

Subjects
--------

The data of patients who received CMII-HRM between June 2011 and February 2018 were reviewed. EGJOO was defined when median IRP was elevated (\> 20 mmHg) without meeting the criteria of achalasia according to the Chicago classification.[@b5-jnm-25-075] Median IRP 20 mmHg was adopted as cutoff for diagnosing EGJOO in Sandhill HRM with reference to previous studies.[@b9-jnm-25-075],[@b20-jnm-25-075]--[@b22-jnm-25-075] As a result, a total of 169 patients with EGJOO were included in the analysis. Clinically relevant patients were defined as follows: (1) subsequent HRM met achalasia criteria during follow-up (early achalasia); (2) Eckardt score was decreased at least two points without exceeding a score of 3 after pneumatic dilatation (variant achalasia); or (3) significant passage disturbance on esophagogram without structural abnormality (possible achalasia).[@b9-jnm-25-075] The study was performed in accordance with the ethical guidelines of the Declaration of Helsinki and approved by the institutional review board at Samsung Medical Center (IRB No. 2018-03-101). Since the study was based on the retrospective analysis of existing administrative and clinical data, the requirement of obtaining informed consent was waived by the institutional review board.

Multichannel Intraluminal Impedance and Esophageal Manometry
------------------------------------------------------------

CMII-HRM was conducted by using a high-resolution impedance manometry system (Sandhill Scientific, Inc, Highlands Ranch, CO, USA). Manometric and Impedance data were analyzed automatically using BioView Analysis (Sandhill Scientific) software, and then each study was blindly reviewed manually. The probe had 32 circumferential pressure sensors spaced 1 cm apart and 16 impedance channels with a 2-cm spacing. CMII-HRM was conducted in standard fashion with a series of 10 swallows of 5-mL normal saline with the subject in the supine position. Bolus entry was defined as a \> 50% drop in impedance level from the baseline at the proximal recording site, and complete bolus transit (CBT) was defined as a \> 50% drop from the baseline followed by an increase of at least 50% towards the original baseline at the 3 distal impedance recording sites after bolus entry.[@b23-jnm-25-075] MII findings were reported as having normal bolus transit if ≥ 80% of liquid swallows had CBT.[@b16-jnm-25-075],[@b24-jnm-25-075],[@b25-jnm-25-075]

HRM metrics were established based on the Chicago classification version 3.0.[@b5-jnm-25-075] The contraction amplitude of the esophageal body was assessed with the distal contractile integral (DCI), and the propagation of contractions along the esophageal body was assessed with distal latency (DL). CP was defined when pressurization was \> 30 mmHg, extending from the contractile front to the esophagogastric junction (EGJ), in at least one swallow during the study. EGJ subtypes were defined as follows: (1) type I EGJ subtype: complete overlap of crural diaphragm and lower esophageal sphincter (LES) components with single peak on the spatial pressure variation plot; (2) type II EGJ subtype: double-peaked pressure zone with the interpeak nadir pressure greater than gastric pressure and a separation of 1--2 cm between peaks; and (3) type III EGJ subtype: double-peaked pressure zone with the interpeak nadir pressure.

Statistical Methods
-------------------

Data are expressed as the mean ± standard deviation, median (range), or n (%) as appropriate. Clinicomanometric characteristics were compared between the patients with clinically relevant EG-JOO and those with non-clinically relevant EGJOO. Differences among the continuous and categorical variables were examined for statistical significance using the Student's *t* test (or Mann-Whitney *U* test, if appropriate) and chi-square test (or Fisher's exact test, if appropriate), respectively. A *P*-value of less than 0.05 with a two-tailed test was considered significant. All statistical analyses were performed using SPSS version 24.0 (IBM Corp, Armonk, NY, USA).

Results
=======

Baseline Characteristics
------------------------

The clinicomanometric baseline characteristics of the patients are summarized in [Table 1](#t1-jnm-25-075){ref-type="table"}. A total of 169 patients were included in the analysis. The mean age of the patients was 56 ± 12 years, and the proportion of males was 30.2% (n = 51). The mean follow-up duration was 26.2 ± 24.4 months. The mean IRP was 24.0 mmHg (range, 20.0--74.0 mmHg), and no statistically significant difference in IRP was found between the clinically relevant and non-clinically relevant groups (25.5 vs 24.0 mmHg, *P* = 0.122). In addition, other manometric variables did not differ between the 2 groups.

Predictors Associated With Clinically Relevant Esophagogastric Junction Outflow Obstruction
-------------------------------------------------------------------------------------------

Among the 169 patients with EGJOO, 10 were clinically relevant, whereas 159 were not ([Fig. 1](#f1-jnm-25-075){ref-type="fig"}). Dysphagia (100% vs 25.2%, *P* \< 0.001), CP (90.0% vs 22.0%, *P* \< 0.001), and abnormal liquid bolus transit (LBT; 100% vs 66.7%, *P* = 0.032) were more common in the clinically relevant group than in the non-clinically relevant group. However, age, sex, follow-up duration, EGJ subtype, IRP, DCI, and DL did not differ significantly between the 2 groups ([Table 1](#t1-jnm-25-075){ref-type="table"}).

Prediction of Clinically Relevant Esophagogastric Junction Outflow Obstruction
------------------------------------------------------------------------------

The proportions of patients with clinically relevant EGJOO who only had dysphagia, CP, or abnormal LBT were 20.0%, 20.5%, and 8.6%, respectively. Of the patients with two predictors (CP with dysphagia, CP with abnormal LBT, and dysphagia with abnormal LBT), 34.6%, 25.0%, and 25.0% had clinically relevant EGJOO, respectively. Notably, among the patients who had all 3 predictors, 42.9% were clinically relevant ([Table 2](#t2-jnm-25-075){ref-type="table"} and [Fig. 2](#f2-jnm-25-075){ref-type="fig"}). The predictive performance of these predictors for clinically relevant EGJOO was higher when these predictors were combined ([Table 3](#t3-jnm-25-075){ref-type="table"}). The combination of all 3 predictors showed the best predictive power for clinically relevant EGJOO (sensitivity 90%, specificity 92.5%, positive predictive value 42.9%, and negative predictive value 99.3%). When we used impedance in addition to dysphagia and CP, we could predict clinically relevant EGJOO more precisely ([Fig. 3](#f3-jnm-25-075){ref-type="fig"}).

Discussion
==========

Owing to the unclear clinical significance of EGJOO, it is important to know which variables can identify clinically relevant EGJOO. This study is the first to present predictors that segregate clinically significant EGJOO by combining impedance test with clinicomanometric variables.

The secondary cause of EGJOO includes mechanical obstruction such as esophageal stenosis, infiltrative disease, cancer, and hiatal hernia.[@b1-jnm-25-075]--[@b3-jnm-25-075],[@b5-jnm-25-075] Thus, it is essential to evaluate the structural cause of IRP elevation. Some patients might evolve to achalasia or have significant dysphagia with passage disturbance requiring intervention.[@b8-jnm-25-075],[@b26-jnm-25-075] Owing to its diagnostic heterogeneity of EGJOO, it is important to find predictors that can segregate clinically relevant EGJOO.

In a previous study, patients with clinically relevant EGJOO had significantly higher rates of dysphagia (100% vs 24.3%, *P* \< 0.001) and CP (85.7% vs 21.7%, *P* = 0.001) than those with non-clinically relevant EGJOO.[@b9-jnm-25-075] Of patients with EGJOO with both dysphagia and CP, 40% had clinically relevant EGJOO. The predictive performance was a little disappointing. Moreover, there was no evaluation items for functional aspects that were expected to be important in predicting clinical significance. This study was performed to overcome these limitations. In effect, MII, which is used to evaluate the functional aspect of esophageal contraction, demonstrated its effectiveness in several studies.[@b18-jnm-25-075],[@b27-jnm-25-075],[@b28-jnm-25-075] In the present study, an objective dysfunctional result, which is abnormal bolus transit, was also a statistically significant factor for segregating clinically relevant EGJOO. Our study showed that patients who had all 3 predictors are more likely to have clinical significance ([Fig. 2](#f2-jnm-25-075){ref-type="fig"}). This multidimensional approach, including symptom, manometric finding, and impedance test, would improve the reliability of EGJOO diagnosis.

Zheng et al[@b29-jnm-25-075] reported that EGJOO is associated with often coexistent abnormal bolus transit. In addition, a study by Jain et al[@b23-jnm-25-075] reported that bolus transit is impaired in EGJOO, but not as severely as in achalasia. These studies clearly showed the association between abnormal bolus transit and EGJOO. The role of CMII-HRM for early diagnosis of achalasia or in the evaluation of potential progress of EGJOO to achalasia (early achalasia) was studied, with promising results.[@b30-jnm-25-075] In addition, Tutuian and Castell[@b18-jnm-25-075] reported that none of the patients with achalasia and scleroderma had normal bolus transit, whereas almost all patients with normal esophageal manometry, nutcracker esophagus, poorly relaxing LES, hypertensive LES, and hypotensive LES had normal bolus transit. These studies consistently suggested that patients with clinically relevant EGJOO tend to have abnormal bolus transit. Thus, we can infer that bolus transit measured using an impedance test might be a significant variable for differentiating between clinically relevant EGJOO and non-clinically relevant EGJOO.

Recently, HRM for the diagnosis of esophageal motility disorders has been widely used, and the diagnostic rate of EGJOO has been increasing. However, no standardized treatment approach has been developed for EGJOO. In most cases, follow-up or sphincter disruption therapy is performed according to the physician's clinical judgment after excluding the structural cause by additional tests such as esophagogastroduodenoscopy, endoscopic ultrasonography, and computed tomography.[@b4-jnm-25-075] According to the present study, approximately 40% of patients with dysphagia, CP, and abnormal bolus transit were found to have clinically relevant EGJOO. Therefore, patients who had all 3 predictors need to be carefully followed up or considered for sphincter disruption therapy. If these predictors are absent or only 1 or 2 are present, IRP elevation is likely to be a coincidental finding.

Our study has a limitation in that only 10 patients with clinically relevant EGJOO were included. Therefore, the generalization of the results may be limited. Also, this is a retrospective study in a single center. However, this study has novelty by objectively defining clinically relevant EGJOO and finding significant predictors through statistical comparisons. Also, our study has sufficient mean follow-up period of 26 months so we could identify clinically relevant EGJOO more precisely. Furthermore, our study will be useful in clinical practice by presenting specific figures of predictive performance and proportions of clinically relevant EGJOO. Future studies with more patients are needed to identify more variables for predicting clinically relevant EGJOO. Studies involving patient symptoms, HRM parameters, and impedance may help develop an approach for this uncertain diagnostic category.

In conclusion, clinically relevant EGJOO can be predicted using a multidimensional approach that considers the functional aspect of esophageal contraction and clinicomanometric characteristics.
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![Improved esophageal bolus clearance after peroral endoscopic myotomy (POEM) in a patient with esophagogastric junction outflow obstruction (EGJOO). A 50-year-old woman presented with dysphagia. (A) She was diagnosed as having EGJOO (integrated relaxation pressure, 41 mmHg) and showed abnormal liquid bolus transit (LBT; 0%). POEM was performed because no organic cause was found to explain her abnormal dysphagia. (B) After POEM, her symptoms disappeared completely, and the LBT was normalized as indicated by the purple color in the figure.](jnm-25-075f1){#f1-jnm-25-075}

![Prediction of clinical relevance of esophagogastric junction outflow obstruction (EGJOO) according to the number of predictors. \**P* \< 0.001 vs predictors 0, 1, or 2, each.](jnm-25-075f2){#f2-jnm-25-075}

![Added value of impedance for prediction of clinically relevant esophagogastric junction outflow obstruction. CP, compartmentalized pressurization; CMII-HRM, combined multichannel intra-luminal impedance and high-resolution manometry; HRM, high-resolution manometry.](jnm-25-075f3){#f3-jnm-25-075}

###### 

Comparison of Clinicomanometric and Impedance Variables between Clinically Relevant and Non-clinically Relevant Esophagogastric Junction Outflow Obstructions

  Variables                           Total (n = 169)     Relevant (n = 10)   Non-relevant (n = 159)   *P*-value
  ----------------------------------- ------------------- ------------------- ------------------------ -----------
  Age (yr)                            56 ± 12             59 ± 9              55 ± 12                  0.297
  Male                                51 (30.2)           4 (40.0)            47 (29.6)                0.491
  Follow-up (mo)                      26.2 ± 24.4         11.2 ± 23.7         27.2 ± 24.2              0.071
  Dysphagia as chief complaint        50 (29.6)           10 (100)            40 (25.2)                \< 0.001
  Manometric variables                                                                                 
   EGJ subtype                                                                                         0.852
    Type I                            131 (77.5)          8 (80.0)            123 (77.4)               
    Type II                           25 (14.8)           1 (10.0)            24 (15.1)                
    Type III                          13 (7.7)            1 (10.0)            12 (7.5)                 
   IRP (mmHg)                         24.0 (20.0--74.0)   25.5 (20.0--50.0)   24.0 (20.0--74.0)        0.122
   DCI (mmHg sec cm)                  2155.4 ± 2172.5     3514.3 ± 5888.6     2070.0 ± 1708.5          0.459
   DL (sec)                           6.4 (0.0--12.9)     6.2 (1.0--10.0)     6.4 (0.0--12.9)          0.788
   Compartmentalized pressurization   44 (26.0)           9 (90.0)            35 (22.0)                \< 0.001
  \% LBT                              50 (0--100)         0 (0--50)           60 (0--100)              \< 0.001
  Abnormal LBT                        116 (68.6)          10 (100)            106 (66.7)               0.032

EGJ, esophagogastric junction; IRP, integrated relaxation pressure; DCI, distal contractile integral; DL, distal latency; LBT, liquid bolus transit.

Data are expressed as the mean ± SD, n (%), or median (range).

###### 

Proportions of Clinically Relevant Esophagogastric Junction Outflow Obstruction According to Presence of Dysphagia, Compartmentalized Pressurization, and Liquid Bolus Transit

  Predictors                      Clinically relevant EGJOO/Patients having variable(s) (%)
  ------------------------------- -----------------------------------------------------------
  Dysphagia                       10/50 (20.0)
  CP                              9/44 (20.5)
  Abnormal LBT                    10/116 (8.6)
  CP + dysphagia                  9/26 (34.6)
  CP + abnormal LBT               9/36 (25.0)
  Dysphagia + abnormal LBT        10/40 (25.0)
  Dysphagia + CP + abnormal LBT   9/21 (42.9)

EGJOO, esophagogastric junction outflow obstruction; CP, compartmentalized pressurization; LBT, liquid bolus transit.

###### 

Predictive Performance of Dysphagia, Compartmentalized Pressurization, and Liquid Bolus Transit for Clinically Relevant Esophagogastric Junction Outflow Obstruction

  Predictors                      Sensitivity (%)   Specificity (%)   PPV (%)   NPV (%)   LR+    LR−
  ------------------------------- ----------------- ----------------- --------- --------- ------ -----
  Dysphagia                       100               74.8              20.0      100       4.0    0.0
  CP                              90.0              78.0              20.5      99.2      4.1    0.1
  LBT                             100               33.3              8.6       100       1.5    0.0
  Dysphagia + CP                  90.0              89.3              34.5      99.3      8.4    0.1
  CP + abnormal LBT               90                83.0              25.0      99.3      5.3    0.1
  Dysphagia + abnormal LBT        100               81.1              25.0      100       5.3    0.0
  CP + dysphagia + abnormal LBT   90                92.5              42.9      99.3      11.9   0.1

PPV, positive predictive value; NPV, negative predictive value; LR+, positive likelihood ratio; LR−, negative likelihood ratio; CP, compartmentalized pressurization; LBT, liquid bolus transit.
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